

## BACKGROUND

Late Onset Pompe Disease (LOPD) is a metabolic, autosomal recessive disease due to a reduced functionality of protein  $\alpha$ -glucosidase (GAA), which leads to an accumulation of glycogen in skeletal muscle tissue and in other organs. 70% of LOPD patients develops progressive respiratory failure (RF) with vital capacity reduction and risk of mechanical ventilation.

Recent data suggest the importance of an early LOPD diagnosis.

## OBJECTIVES

- Prevalence of LOPD suspect in patients with respiratory failure
- Optimize the diagnostic process in pulmonology units, encouraging early diagnosis

## METHODS

- Real-life study, conducted in 18 Pulmonology Italian Centers (Fig. 1), aimed to enroll 500 adult patients with unexplained RF and follow the diagnostic algorithm for suspected LOPD (Fig. 2a-2b)
- For each patient, clinicians collected a drop of blood on Dried Blood Spot (DBS) for the measurement of GAA, executed in a centralized laboratory
- Muscular disability was assessed with Walton Gardner Medwin Scale (WGMS).

Fig. 1 – Centers distribution




Fig. 2a - LOPD diagnostic algorithm (1)





Fig. 2b - Diagnostic flow chart to confirm the diagnosis of LOPD on the basis of different respiratory dysfunctional patterns (2)



## PRELIMINARY RESULTS

PneumoLoped started in February 2015 (enrollment is ongoing). **67 patients have been enrolled at the date of this analysis** (characteristics in Table 1 and Fig. 3-7):

- 43% acceded for respiratory reasons
- 45% was hospitalized and 33% needed mechanical ventilation
- Hyperckemia was reported in 39% of patients
- The majority of cases (78%) presented a WGMS between 0 and 5

Table 1 – Patients characteristics (n. 67) [m.s. = missing data]

Gender (n, %)	M: 41 (61%), F: 26 (39%)
Age, Y (mean±sd)	59±18
NM Family history (n, %)	3 (4%)
FEV1 % pred (n,%)	normal: 25 (37%); low: 33 (49%); 14% m.s.
FEV1/VC% (n,%)	normal: 40 (60%); low: 16 (24%); 16% m.s.
MIP (n,%)	normal: 5 (7%); low: 41 (61%); 32% m.s.
MEP (n,%)	normal: 12 (18%); low: 34 (51%); 31% m.s.
SpO2 (n,%)	>30% of night time < 90%: 11 (16%); at least 5 min <90%: 16 (24%); at nadir <85%: 2 (3%); 57% m.s.
PaO2 (n,%)	normal: 22 (33%); hypoxemia: 31 (46%); respiratory failure: 4 (6%); 15% m.s.
PaCO2 (n,%)	normal: 29 (43%); hypocapnia: 7 (10%); hypercapnia: 21 (31%); 16% m.s.
PH (n,%)	compensated: 48 (72%); alkalosis: 6 (9%); acidosis: 3 (4%); 15% m.s.
Bicarbonates (n,%)	normal: 29 (43%); low: 3 (4%); high: 23 (34%); 19% m.s.
CK (n,%)	≤ 195: 21 (31%); >195: 26 (39%); 30% m.s.

Fig. 3 – Cause of visit




Fig. 4 – Patient access




Fig. 5 – Walton & Gardner-Medwin (WGM) scale




Fig. 7 - Other diseases





Fig. 6 – Clinical signs and symptoms



## GGA ACTIVITY MEASUREMENTS

- 66 blood samples has been collected on DBS (1 is going to be collected)
- 64 has been already analyzed in a centralized laboratory through *tandem mass spectrometry*

### Results:

- 63 cases resulted negative [ $>1,86$  micromol/L/h]
- 1 subject resulted **positive** [0,48 micromol/L/h at first test; 0,36 micromol/L/h at second test]

## CONCLUSIONS

PNEUMOLOPED COULD PROVIDE ORIGINAL DATA TO BETTER HIGHLIGHT THE ROLE OF PULMONOLOGISTS IN THE MANAGEMENT OF ACUTE RESPIRATORY FAILURE ASSOCIATED TO NEUROMUSCULAR DISEASES, AND IN THE ASSISTANCE OF SUBJECTS WITH GENETIC RARE DISORDERS SUCH AS LATE ONSET POMPE DISEASE.

## REFERENCES

- Toscano A, Montagnese F, Musumeci O. *Early is better? A new algorithm for early diagnosis in Late Onset Pompe Disease (LOPD)* Acta Myologica 2013; XXXII: 78-81
- Ambrosino N, Confalonieri M, Crescimanno G et Al. *The role of respiratory management of Pompe disease.* Respiratory Medicine 2013; 107: 1124-1132